Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Everest Starts China Trial of Treatment for Rare Renal Disease

publication date: Sep 8, 2020

Everest Medicines, a Shanghai in-licensing company, has begun dosing patients in a China Phase III trial of a treatment for autoimmune renal disease. Everest acquired China rights to Nefecon from Calliditas Therapeutics of Stockholm. Calliditas has completed a Phase III trial of the candidate in patients with IgA nephropathy (IgAN), a rare renal disease for which there are no treatments. Everest will enroll some China patients in the 160-person global Part B Phase III trial, which is being conducted to validate the biomarker, proteinuria. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China